Full Press Release Details
dupixent dupilumab approved in the u s as first and only treatment for adolescents with chronic rhinosinusitis with nasal polyps crswnp.
REGN
dupixent dupilumab approved in the u s as first and only treatment for adolescents with chronic rhinosinusitis with nasal polyps crswnp
Key Takeaway: dupixent dupilumab approved in the u s as first and only treatment for adolescents with chronic rhinosinusitis with nasal polyps crswnp